{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:29:10Z","timestamp":1794608950515,"version":"4.9.1"},"reference-count":253,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2018-12367402"],"award-info":[{"award-number":["RF-2018-12367402"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-15614"],"award-info":[{"award-number":["AI-15614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["22136"],"award-info":[{"award-number":["22136"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010279","name":"Interleukin Foundation for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.autrev.2021.102763","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T23:33:54Z","timestamp":1611099234000},"page":"102763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":354,"title":["Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases"],"prefix":"10.1016","volume":"20","author":[{"given":"Giulio","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Colafrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2021.102763_bb0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin-1\u03b1 and the inflammatory process","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat Immun"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4049\/jimmunol.1601342","article-title":"Alarmins: feel the stress","volume":"198","author":"Rider","year":"2017","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.smim.2013.10.005","article-title":"Interleukin-1\u03b1","volume":"25","author":"Rider","year":"2013","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imr.12615","article-title":"Function and regulation of IL-1\u03b1 in inflammatory diseases and cancer","volume":"281","author":"Malik","year":"2018","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12612","article-title":"Biology of IL-38 and its role in disease","volume":"281","author":"van de Veerdonk","year":"2018","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0035","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.4049\/jimmunol.123.6.2928","article-title":"Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors","volume":"123","author":"Aarden","year":"1979","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0040","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.139.6.1369","article-title":"Demonstration and characterization of two distinct human leukocytic pyrogens","volume":"139","author":"Dinarello","year":"1974","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102763_bb0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fimmu.2013.00391","article-title":"The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines","volume":"4","author":"Kim","year":"2013","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2013.01.008","article-title":"Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation","volume":"38","author":"Zheng","year":"2013","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/imr.12609","article-title":"Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8","volume":"281","author":"Molgora","year":"2018","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-065X.2011.01046.x","article-title":"The inflammasome: an integrated view","volume":"243","author":"Gross","year":"2011","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2021.102763_bb0075","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.4049\/jimmunol.138.12.4249","article-title":"Subcellular localization of human monocyte interleukin 1: evidence for an inactive precursor molecule and a possible mechanism for IL-1 release","volume":"138","author":"Bakouche","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0080","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4049\/jimmunol.143.4.1183","article-title":"Membrane IL-1: IL-1\u03b1 precursor binds to the plasma membrane via a lectin-like interaction","volume":"143","author":"Brody","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0085","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1073\/pnas.82.4.1204","article-title":"Identification of a membrane-associated interleukin-1 in macrophages","volume":"82","author":"Kurt-Jones","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0090","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0915018107","article-title":"Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation","volume":"107","author":"Cohen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2021.102763_bb0095","doi-asserted-by":"crossref","first-page":"22100","DOI":"10.1016\/S0021-9258(20)80653-X","article-title":"Identification of a nuclear localization sequence within the structure of the human interleukin-1\u03b1 precursor","volume":"268","author":"Wessendorf","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2021.102763_bb0100","doi-asserted-by":"crossref","first-page":"19100","DOI":"10.1038\/srep19100","article-title":"Corrigendum: IL-1\u03b1 is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity","volume":"6","author":"Cohen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2021.102763_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","article-title":"Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation","volume":"55","author":"Bessa","year":"2014","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0110","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1073\/pnas.1821111116","article-title":"Role for nuclear interleukin-37 in the suppression of innate immunity","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0125","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.immuni.2015.11.016","article-title":"Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection","volume":"43","author":"Di Paolo","year":"2015","journal-title":"Immunity."},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0130","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1128\/IAI.72.4.2338-2349.2004","article-title":"Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis","volume":"72","author":"Maffei","year":"2004","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/intimm\/dxq006","article-title":"IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB\/c mice","volume":"22","author":"Voronov","year":"2010","journal-title":"Int Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.molcel.2018.07.009","article-title":"An Antiviral Branch of the IL-1 Signaling Pathway Restricts Immune-Evasive Virus Replication","volume":"71","author":"Orzalli","year":"2018","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0145","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1073\/pnas.0611608104","article-title":"Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha","volume":"104","author":"Hurgin","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0150","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1006\/geno.2002.6751","article-title":"A sequence-based map of the nine genes of the human interleukin-1 cluster","volume":"79","author":"Nicklin","year":"2002","journal-title":"Genomics."},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"19","key":"10.1016\/j.autrev.2021.102763_bb0160","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1073\/pnas.83.19.7429","article-title":"Isolation and characterization of a primitive interleukin-1-like protein from an invertebrate, Asterias forbesi","volume":"83","author":"Beck","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0165","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41467-018-03362-1","article-title":"Redefining the ancestral origins of the interleukin-1 superfamily","volume":"9","author":"Rivers-Auty","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0955-2235(89)90012-4","article-title":"The fibroblast growth factor family: structural and biological properties","volume":"1","author":"Klagsbrun","year":"1989","journal-title":"Prog Grow Fact Res"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0175","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jmb.2020.01.015","article-title":"Autophagy and Protein Secretion","volume":"432","author":"Cavalli","year":"2020","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0180","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2019-216233","article-title":"Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout","volume":"79","author":"Kluck","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.201040319","article-title":"IL-1: discoveries, controversies and future directions","volume":"40","author":"Dinarello","year":"2010","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0190","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity."},{"key":"10.1016\/j.autrev.2021.102763_bb0195","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1016\/j.smim.2013.10.019","article-title":"Negative regulatory receptors of the IL-1 family","volume":"25","author":"Garlanda","year":"2013","journal-title":"Semin Immunol"},{"issue":"5120","key":"10.1016\/j.autrev.2021.102763_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.8332913","article-title":"Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4","volume":"261","author":"Colotta","year":"1993","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0205","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1002\/j.1460-2075.1991.tb07831.x","article-title":"A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types","volume":"10","author":"McMahan","year":"1991","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0210","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1084\/jem.183.4.1841","article-title":"Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface \u201creceptor\u201d with anti-interleukin-1 function","volume":"183","author":"Re","year":"1996","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0215","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1073\/pnas.92.5.1714","article-title":"Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist","volume":"92","author":"Symons","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0220","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ni.2406","article-title":"From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines","volume":"13","author":"Banchereau","year":"2012","journal-title":"Nat Immunol"},{"issue":"37","key":"10.1016\/j.autrev.2021.102763_bb0225","doi-asserted-by":"crossref","first-page":"14224","DOI":"10.1074\/jbc.RA118.003698","article-title":"Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue","volume":"293","author":"Ballak","year":"2018","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0230","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1073\/pnas.1619011114","article-title":"Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance","volume":"114","author":"Cavalli","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0235","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"51","key":"10.1016\/j.autrev.2021.102763_bb0240","doi-asserted-by":"crossref","first-page":"20684","DOI":"10.1073\/pnas.1116848108","article-title":"Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha","volume":"108","author":"Berda-Haddad","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.autrev.2021.102763_bb0245","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102763_bb0250","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0255","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1525-1470.2008.00765.x","article-title":"Neutrophilic dermatoses in children","volume":"25","author":"Berk","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0265","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting interleukin-1 alpha for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0270","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.4049\/jimmunol.1800760","article-title":"Cutting edge: dysregulated CARD9 signaling in neutrophils drives inflammation in a mouse model of neutrophilic dermatoses","volume":"201","author":"Tartey","year":"2018","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0275","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjd.15105","article-title":"Are neutrophilic dermatoses autoinflammatory disorders?","volume":"178","author":"Satoh","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00281-015-0549-6","article-title":"Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders","volume":"38","author":"Navarini","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0285","first-page":"1946","article-title":"Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts","volume":"31","author":"Kawaguchi","year":"2004","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0290","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"J Clin Invest"},{"issue":"4889","key":"10.1016\/j.autrev.2021.102763_bb0295","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.2783498","article-title":"Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA","volume":"243","author":"Raines","year":"1989","journal-title":"Science."},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0300","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9589","key":"10.1016\/j.autrev.2021.102763_bb0305","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(07)61383-X","article-title":"From COPD to chronic systemic inflammatory syndrome?","volume":"370","author":"Fabbri","year":"2007","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0310","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/thx.2010.156448","article-title":"Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer","volume":"66","author":"Caramori","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1164\/ajrccm.162.1.9911019","article-title":"Respiratory viral infections in adults with and without chronic obstructive pulmonary disease","volume":"162","author":"Greenberg","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0320","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/rccm.201006-0833OC","article-title":"Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation","volume":"183","author":"Mallia","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0325","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/mi.2013.87","article-title":"IL-1\u03b1 released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts","volume":"7","author":"Suwara","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0330","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1206378","article-title":"IL-1\u03b1 mediates cellular cross-talk in the airway epithelial mesenchymal trophic unit","volume":"4","author":"Hill","year":"2016","journal-title":"Tissue Barriers"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063365","article-title":"The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells","volume":"8","author":"Piper","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0340","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1183\/13993003.01911-2015","article-title":"Interleukin-1\u03b1 drives the dysfunctional cross-talk of the airway epithelium and lung fibroblasts in COPD","volume":"48","author":"Osei","year":"2016","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0345","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bjc.2012.429","article-title":"Interleukin-1\u03b1 is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts","volume":"107","author":"Tracy","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir Res"},{"issue":"10082","key":"10.1016\/j.autrev.2021.102763_bb0355","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet."},{"issue":"3\u20134","key":"10.1016\/j.autrev.2021.102763_bb0360","first-page":"181","article-title":"Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis","volume":"48","author":"Ogushi","year":"2001","journal-title":"J Med Investig"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0365","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2019.11.005","article-title":"Connective tissue disease related interstitial lung disease","volume":"13","author":"Schulte","year":"2020","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0370","first-page":"315","article-title":"Increased incidence of autoantibodies to interleukin-1a in rheumatoid arthritis with interstitial lung disease","volume":"5","author":"Maniwa","year":"2000","journal-title":"Respirology."},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0375","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb0380","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0385","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10067-006-0308-0","article-title":"T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis","volume":"26","author":"Beretta","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/1346-8138.12011","article-title":"Serum levels of interleukin-1\u03b1 in patients with systemic sclerosis","volume":"40","author":"Maekawa","year":"2013","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0395","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.23451","article-title":"Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma","volume":"58","author":"Duan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0400","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1045","article-title":"Analysis of serum interleukin(IL)-1\u03b1, IL-1\u03b2 and IL-18 in patients with systemic sclerosis","volume":"8","author":"Lin","year":"2019","journal-title":"Clin Transl Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0405","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/jid.2010.120","article-title":"Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis","volume":"130","author":"Aden","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0410","doi-asserted-by":"crossref","first-page":"1900154","DOI":"10.1183\/13993003.00154-2019","article-title":"IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis","volume":"54","author":"Birnhuber","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0415","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","article-title":"Interstitial lung disease in systemic sclerosis: current and future treatment","volume":"37","author":"Giacomelli","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0420","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2018.05.006","article-title":"Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis","volume":"17","author":"Montgomery","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.autrev.2021.102763_bb0425","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3389\/fimmu.2019.01555","article-title":"Developmentally regulated innate immune NF\u03baB signaling mediates IL-1\u03b1 expression in the perinatal murine lung","volume":"10","author":"Butler","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0430","first-page":"L49","article-title":"Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates","volume":"317","author":"Eldredge","year":"2019","journal-title":"Am J Phys Lung Cell Mol Phys"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0435","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ibd.21287","article-title":"IL-1 receptor-associated kinase M downregulates DSS-induced colitis","volume":"16","author":"Berglund","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0440","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.4049\/jimmunol.154.5.2434","article-title":"Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation","volume":"154","author":"Casini-Raggi","year":"1995","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0445","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12307-015-0177-7","article-title":"IL-1 in colon inflammation, colon carcinogenesis and invasiveness of colon cancer","volume":"8","author":"Voronov","year":"2015","journal-title":"Cancer Microenviron"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0450","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/gutjnl-2012-303329","article-title":"Non-redundant properties of IL-1\u03b1 and IL-1\u03b2 during acute colon inflammation in mice","volume":"63","author":"Bersudsky","year":"2014","journal-title":"Gut."},{"issue":"52","key":"10.1016\/j.autrev.2021.102763_bb0455","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1073\/pnas.1915043116","article-title":"Neutralization of IL-1\u03b1 ameliorates Crohn\u2019s disease-like ileitis by functional alterations of the gut microbiome","volume":"116","author":"Menghini","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0460","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5858\/2008-132-232-MIAOCI","article-title":"Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy","volume":"132","author":"Baird","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0465","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/BOR.0b013e3283317b31","article-title":"Role of cytokines and chemokines in idiopathic inflammatory myopathies","volume":"21","author":"De Paepe","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0470","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00002281-199811000-00004","article-title":"New developments in the role of cytokines and chemokines in inflammatory myopathies","volume":"10","author":"Lundberg","year":"1998","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0475","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2990.1997.tb01195.x","article-title":"Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes","volume":"23","author":"Authier","year":"1997","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0480","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.10140","volume":"46","author":"Englund","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0485","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V","article-title":"Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis","volume":"43","author":"Lundberg","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0490","first-page":"940","article-title":"Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis","volume":"27","author":"Nyberg","year":"2000","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0495","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.22388","article-title":"Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies","volume":"56","author":"Grundtman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0500","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0505","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/art.34465","article-title":"Interleukin-1 and tumor necrosis factor alpha blockade treatment of experimental polymyositis in mice","volume":"64","author":"Sugihara","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0510","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0515","first-page":"904","article-title":"Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy","volume":"33","author":"Groh","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"15","key":"10.1016\/j.autrev.2021.102763_bb0520","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMra0800028","article-title":"Myocarditis","volume":"360","author":"Cooper","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0525","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0530","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3389\/fimmu.2018.01335","article-title":"Myocarditis: An Interleukin-1-Mediated Disease?","volume":"9","author":"De Luca","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0535","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0540","doi-asserted-by":"crossref","first-page":"H1438","DOI":"10.1152\/ajpheart.00441.2014","article-title":"Involvement of NLRP3 inflammasome in CVB3-induced viral myocarditis","volume":"307","author":"Wang","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.autrev.2021.102763_bb0545","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2015.08.070","article-title":"Formation of the inflammasome during cardiac allograft rejection","volume":"201","author":"Shah","year":"2015","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0550","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1113\/expphysiol.2012.069021","article-title":"The heart on fire: inflammasome and cardiomyopathy","volume":"98","author":"Abbate","year":"2013","journal-title":"Exp Physiol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0555","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.RES.81.4.493","article-title":"Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes","volume":"81","author":"McTiernan","year":"1997","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0560","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0735-1097(00)00526-X","article-title":"Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes","volume":"35","author":"Tatsumi","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.autrev.2021.102763_bb0565","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb0570","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/L18-0315","article-title":"Treatment of dilated cardiomyopathy with interleukin-1 inhibition","volume":"169","author":"De Luca","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102763_bb0575","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure","volume":"8","author":"Cavalli","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0580","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1","volume":"44","author":"Cavalli","year":"2016","journal-title":"Crit Care Med"},{"issue":"24","key":"10.1016\/j.autrev.2021.102763_bb0585","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006656","article-title":"Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8 mg\/kg\/d) of anakinra","volume":"96","author":"Parisi","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"16","key":"10.1016\/j.autrev.2021.102763_bb0590","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.autrev.2021.102763_bb0595","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1606915","article-title":"Acute myocardial infarction","volume":"376","author":"Anderson","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0600","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0605","doi-asserted-by":"crossref","first-page":"H1117","DOI":"10.1152\/ajpheart.00372.2009","article-title":"Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts","volume":"297","author":"Turner","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0610","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0008-6363(00)00032-8","article-title":"Infarct scar: a dynamic tissue","volume":"46","author":"Sun","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2021.102763_bb0615","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biological basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood."},{"issue":"12 Suppl 1","key":"10.1016\/j.autrev.2021.102763_bb0620","article-title":"Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis","volume":"104","author":"Suzuki","year":"2001","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0625","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/01.CCM.0000233878.36340.10","article-title":"Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury","volume":"34","author":"Furuichi","year":"2006","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0630","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/glia.20308","article-title":"Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia","volume":"53","author":"Pinteaux","year":"2006","journal-title":"Glia."},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0635","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2353\/ajpath.2008.070974","article-title":"Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling","volume":"173","author":"Bujak","year":"2008","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0640","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/FJC.0000000000000452","article-title":"Reduction of myocardial ischemia-reperfusion injury by inhibiting interleukin-1 alpha","volume":"69","author":"Mauro","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0645","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","article-title":"Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse","volume":"98","author":"Toldo","year":"2013","journal-title":"Exp Physiol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0650","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm1603","article-title":"Identification of a key pathway required for the sterile inflammatory response triggered by dying cells","volume":"13","author":"Chen","year":"2007","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0655","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0660","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0665","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0670","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.autrev.2021.102763_bb0675","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseases: a clinical update","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0680","first-page":"505","article-title":"Acute and recurrent pericarditis","volume":"35","author":"Imazio","year":"2017","journal-title":"Cardiol Clin"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0685","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11739-018-1842-x","article-title":"Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism","volume":"13","author":"Brucato","year":"2018","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0690","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.24174","article-title":"Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1\u03b2 receptor antagonist (anakinra): an unrecognized autoinflammatory disease?","volume":"60","author":"Picco","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0695","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14779072.2018.1510315","article-title":"Advances in medical therapy for pericardial diseases","volume":"16","author":"Galluzzo","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"18","key":"10.1016\/j.autrev.2021.102763_bb0700","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA."},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0705","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/2047487319879534","article-title":"Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (international registry of Anakinra for pericarditis) study","volume":"27","author":"Imazio","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"42","key":"10.1016\/j.autrev.2021.102763_bb0710","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2021.102763_bb0715","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.5854","article-title":"IL-1 blockade in pediatric recurrent pericarditis: a multicentric retrospective study on the italian cohort","author":"Caorsi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.autrev.2021.102763_bb0720","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood-2009-11-252643","article-title":"Platelet interleukin-1alpha drives cerebrovascular inflammation","volume":"115","author":"Thornton","year":"2010","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0725","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2019.03.003","article-title":"The coagulation and immune systems are directly linked through the activation of interleukin-1alpha by Thrombin","volume":"50","author":"Burzynski","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.autrev.2021.102763_bb0730","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cyto.2018.01.007","article-title":"Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1beta, IL-6 and IL-8","volume":"110","author":"Bester","year":"2018","journal-title":"Cytokine."},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0735","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1055\/s-0038-1675603","article-title":"The inter-relationship of platelets with interleukin-1beta-mediated inflammation in humans","volume":"118","author":"Tunjungputri","year":"2018","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0740","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCRESAHA.107.165332","article-title":"Constitutive repression of interleukin-1alpha in endothelial cells","volume":"102","author":"Brunn","year":"2008","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0745","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1083\/jcb.201410052","article-title":"IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs","volume":"209","author":"Nishimura","year":"2015","journal-title":"J Cell Biol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0750","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","article-title":"Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1alpha and Cathepsin G","volume":"38","author":"Folco","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Supplement_3","key":"10.1016\/j.autrev.2021.102763_bb0755","doi-asserted-by":"crossref","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Behcet: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0760","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11739-013-1036-5","article-title":"Behcet\u2019s syndrome pathophysiology and potential therapeutic targets","volume":"9","author":"Emmi","year":"2014","journal-title":"Intern Emerg Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0765","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Behcet's syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0770","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cei.13243","article-title":"Behcet\u2019s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects","volume":"195","author":"Becatti","year":"2019","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0775","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11739-018-1991-y","article-title":"Vascular Behcet\u2019s syndrome: an update","volume":"14","author":"Emmi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.autrev.2021.102763_bb0780","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Behcet\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0785","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12016-012-8319-x","article-title":"Behcet syndrome: is it one condition?","volume":"43","author":"Yazici","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0790","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1172-6-15","article-title":"Hughes-Stovin syndrome","volume":"6","author":"Khalid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0795","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cei.13243","article-title":"Beh\u00e7et\u2019s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects","volume":"195","author":"Becatti","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0800","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et\u2019s syndrome as a model of thrombo-inflammation: The role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0805","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1586\/14779072.2013.836449","article-title":"Vascular Beh\u00e7et\u2019s disease: new insights in the management of thrombosis","volume":"11","author":"Silvestri","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0810","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/rheumatology\/keg232R","article-title":"Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet\u2019s disease","volume":"42","author":"Karasneh","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb0815","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00393-014-1540-7","article-title":"Associations between interleukin-1 polymorphisms and susceptibility to vasculitis: a meta-analysis","volume":"75","author":"Song","year":"2016","journal-title":"Z Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb0820","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.4049\/jimmunol.175.11.7678","article-title":"T cell-regulated neutrophilic inflammation in autoinflammatory diseases","volume":"175","author":"Keller","year":"2005","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0825","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/thorax.56.7.572","article-title":"Pulmonary manifestations of Beh\u00e7et\u2019s disease","volume":"56","author":"Erkan","year":"2001","journal-title":"Thorax."},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb0830","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archderm.140.5.570","article-title":"Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction","volume":"140","author":"Kawakami","year":"2004","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0835","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb0840","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/febs.14075","article-title":"Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines","volume":"284","author":"Clancy","year":"2017","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0845","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.autrev.2021.102763_bb0850","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/ATVBAHA.115.306475","article-title":"IL-1 Signaling Is critically required in stromal cells in Kawasaki disease vasculitis mouse model: role of both IL-1\u03b1 and IL-1\u03b2","volume":"35","author":"Lee","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0855","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jvs.2011.02.061","article-title":"Endovascular aneurysm repair reverses the increased titer and the inflammatory activity of interleukin-1\u03b1 in the serum of patients with abdominal aortic aneurysm","volume":"54","author":"Yates","year":"2011","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0860","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13052-018-0536-3","article-title":"Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase","volume":"44","author":"Marchesi","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0865","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13052-018-0529-2","article-title":"Kawasaki disease: guidelines of the Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks","volume":"44","author":"Marchesi","year":"2018","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.autrev.2021.102763_bb0870","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1086\/428291","article-title":"Association between a novel human coronavirus and Kawasaki disease","volume":"191","author":"Esper","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0875","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13256-019-2028-5","article-title":"Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings","volume":"13","author":"Maggio","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.autrev.2021.102763_bb0880","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.4049\/jimmunol.1600388","article-title":"Inositol- triphosphate 3- kinase C mediates inflammasome activation and treatment response in Kawasaki disease","volume":"197","author":"Alphonse","year":"2016","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.autrev.2021.102763_bb0885","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM198812223192515","article-title":"Circulating interleukin-1 beta in patients with Kawasaki disease","volume":"319","author":"Maury","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102763_bb0890","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/adc.2005.087437","article-title":"The pathophysiology of coronary artery aneurysms in kawasaki disease: Role of matrix metalloproteinases","volume":"91","author":"Senzaki","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.autrev.2021.102763_bb0895","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00210-006-0084-z","article-title":"Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease","volume":"373","author":"Makata","year":"2006","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb0900","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: The role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb0905","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02002715","article-title":"Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease","volume":"155","author":"Suzuki","year":"1996","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb0910","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1253\/circj.CJ-09-0664","article-title":"Il-1beta polymorphism in association with initial intravenous immunoglobulin treatment failure in taiwanese children with kawasaki disease","volume":"74","author":"Weng","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2021.102763_bb0915","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cct.2016.04.002","article-title":"Rationale and study design for a phase I\/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial)","volume":"48","author":"Tremoulet","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb0925","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.autrev.2018.01.024","article-title":"The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series","volume":"17","author":"Kone-Paut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102763_bb0930","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fped.2020.00195","article-title":"Resolution of giant coronary aneurisms in a child with refractory Kawasaki disease treated with Anakinra","volume":"8","author":"Gambacorta","year":"2020","journal-title":"Front Pediatr"},{"issue":"7798","key":"10.1016\/j.autrev.2021.102763_bb0935","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2021.102763_bb0940","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3389\/fimmu.2018.00916","article-title":"Interleukin-1\u03b1 mediates ozone-induced myeloid differentiation factor-88-dependent epithelial tissue injury and inflammation","volume":"9","author":"Michaudel","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0945","doi-asserted-by":"crossref","first-page":"102573","DOI":"10.1016\/j.autrev.2020.102573","article-title":"COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?","volume":"19","author":"Colafrancesco","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102763_bb0950","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"6","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0955","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb0960","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10 Pt 1","key":"10.1016\/j.autrev.2021.102763_bb0965","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1164\/ajrccm.164.10.2104013","article-title":"Cytokine balance in the lungs of patients with acute respiratory distress syndrome","volume":"164","author":"Park","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb0970","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/PCC.0000000000001680","article-title":"Interleukin-1 receptor antagonist is associated with pediatric acute respiratory distress syndrome and worse outcomes in children with acute respiratory failure","volume":"19","author":"Dahmer","year":"2018","journal-title":"Pediatr Crit Care Med"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb0975","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ppul.24090","article-title":"Interleukin 1 receptor antagonist (IL1RA) gene polymorphism and levels associated with adverse outcome in severe community-acquired pneumonia in children: A hospital-based study in India","volume":"53","author":"Awasthi","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.autrev.2021.102763_bb0980","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3389\/fimmu.2020.01439","article-title":"Targeting the immune system for pulmonary inflammation and cardiovascular complications in COVID-19 patients","volume":"11","author":"Colafrancesco","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb0985","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb0990","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2021.102763_bb0995","doi-asserted-by":"crossref","DOI":"10.1002\/art.41422","article-title":"Use of anakinra to prevent mechanical ventilation in severe COVID-19: A case series","author":"Navarro-Mill\u00e1n","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb1000","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb1005","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/rheumatology\/keaa318","article-title":"Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment","volume":"59","author":"Gonz\u00e1lez-Garc\u00eda","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable anakinra responses in severe Covid-19 Patients with secondary hemophagocytic lymphohistiocytosis","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.autrev.2021.102763_bb1015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijid.2020.05.026","article-title":"Use of anakinra in severe COVID-19: A case report","volume":"96","author":"Filocamo","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb1025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijid.2020.05.050","article-title":"Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report","volume":"97","author":"Franzetti","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102763_bb1030","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2021.102763_bb1035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb1040","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"Della-Torre","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb1060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: A single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"10239","key":"10.1016\/j.autrev.2021.102763_bb1065","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2021.102763_bb1070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.048360","article-title":"Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic","author":"Belhadjer","year":"2020","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb1075","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1542\/hpeds.2020-0123","article-title":"COVID-19 and Kawasaki Disease: Novel virus and novel case","volume":"10","author":"Jones","year":"2020","journal-title":"Hosp Pediatr"},{"key":"10.1016\/j.autrev.2021.102763_bb1080","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4 Suppl 98","key":"10.1016\/j.autrev.2021.102763_bb1085","first-page":"58","article-title":"Sj\u00f6gren\u2019s syndrome: from pathogenesis to novel therapeutic targets","volume":"34","author":"Barone","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1090","first-page":"25","article-title":"The role of apoptosis in Sj\u00f6gren\u2019s syndrome","volume":"149","author":"Bolstad","year":"1998","journal-title":"Ann Med Interne (Paris)"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1873-3468.12933","article-title":"How stress contributes to autoimmunity-lessons from Sj\u00f6gren\u2019s syndrome","volume":"592","author":"Skopouli","year":"2018","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0714.2012.01181.x","article-title":"Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling","volume":"42","author":"Nandula","year":"2013","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","article-title":"Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function","volume":"38","author":"Deshmukh","year":"2009","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cei.12644","article-title":"Interleukin-36\u03b1 axis is modulated in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"181","author":"Ciccia","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb1115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126277","article-title":"Upregulation of NLRP3 inflammasome in the tears and ocular surface of dry eye patients","volume":"10","author":"Niu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102763_bb1120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","article-title":"Innate immunity in Sj\u00f6gren\u2019s syndrome","volume":"182","author":"Kiripolsky","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb1125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.exer.2018.03.026","article-title":"Comparative analysis on the dynamic of lacrimal gland damage and regeneration after Interleukin-1\u03b1 or duct ligation induced dry eye disease in mice","volume":"172","author":"Dietrich","year":"2018","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb1130","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.exer.2007.01.015","article-title":"A single injection of interleukin-1 induces reversible aqueous-tear deficiency, lacrimal gland inflammation, and acinar and ductal cell proliferation","volume":"84","author":"Zoukhri","year":"2007","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb1135","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2353\/ajpath.2010.100227","article-title":"Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sj\u00f6gren\u2019s syndrome","volume":"177","author":"Chen","year":"2010","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb1140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered cytokine balance in the tear fluid and conjunctiva of patients with Sj\u00f6gren\u2019s syndrome keratoconjunctivitis sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr Eye Res"},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb1145","first-page":"2283","article-title":"Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.autrev.2021.102763_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2015.09.039","article-title":"Clinical and molecular inflammatory response in Sj\u00f6gren syndrome-associated dry eye patients under desiccating stress","volume":"161","author":"L\u00f3pez-Miguel","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1155","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2249.1996.d01-824.x","article-title":"IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sj\u00f6gren\u2019s syndrome (SS)","volume":"106","author":"Dubost","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102763_bb1160","first-page":"1957","article-title":"Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease","volume":"19","author":"Vijmasi","year":"2013","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102763_bb1165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICL.0000000000000276","article-title":"Multicenter study of a novel topical interleukin-1 receptor inhibitor, Isunakinra, in subjects with moderate to severe dry eye disease","volume":"43","author":"Goldstein","year":"2017","journal-title":"Eye Contact Lens"},{"issue":"1","key":"10.1016\/j.autrev.2021.102763_bb1170","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome--a double blind, randomised clinical trial","volume":"7","author":"Br\u00e6kke Norheim","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/JLB.3MR0120-203RR","article-title":"Erdheim-Chester disease: an in vivo human model of macrophage activation at the crossroad between chronic inflammation and cancer","volume":"108","author":"Cavalli","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102763_bb1180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00415-017-8692-8","article-title":"Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease","volume":"265","author":"Chiapparini","year":"2018","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb1190","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1181244","article-title":"Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease","volume":"5","author":"Ferrero","year":"2016","journal-title":"Oncoimmunology."},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb1195","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-203685","article-title":"Diagnosing Erdheim-Chester disease","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2021.102763_bb1200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440929","article-title":"The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease","volume":"7","author":"Pacini","year":"2018","journal-title":"Oncoimmunology."},{"issue":"10","key":"10.1016\/j.autrev.2021.102763_bb1205","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","article-title":"The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.autrev.2021.102763_bb1210","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2021.102763_bb1215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3389\/fimmu.2018.01233","article-title":"Treating heart inflammation with interleukin-1 blockade in a case of Erdheim-Chester disease","volume":"9","author":"Tomelleri","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb1220","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2015-09-672667","article-title":"Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease","volume":"127","author":"Cohen-Aubart","year":"2016","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.autrev.2021.102763_bb1225","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood-2016-06-725143","article-title":"Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease","volume":"128","author":"Diamond","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1073\/pnas.94.2.508","article-title":"The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein","volume":"94","author":"Stevenson","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.autrev.2021.102763_bb1235","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.ajpath.2015.07.009","article-title":"Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1alpha in an AIM2 inflammasome-dependent manner","volume":"185","author":"Sorrentino","year":"2015","journal-title":"Am J Pathol"},{"issue":"36","key":"10.1016\/j.autrev.2021.102763_bb1240","doi-asserted-by":"crossref","first-page":"58181","DOI":"10.18632\/oncotarget.11276","article-title":"IL-1alpha and IL-1beta-producing macrophages populate lung tumor lesions in mice","volume":"7","author":"Terlizzi","year":"2016","journal-title":"Oncotarget."},{"issue":"7203","key":"10.1016\/j.autrev.2021.102763_bb1245","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb1250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(14)70164-0","article-title":"Interleukin-1alpha neutralisation in patients with cancer","volume":"15","author":"Dinarello","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102763_bb1255","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10637-015-0226-6","article-title":"Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer","volume":"33","author":"Hong","year":"2015","journal-title":"Investig New Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2021.102763_bb1260","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102763_bb1265","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102763_bb1270","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474319","article-title":"Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study","volume":"7","author":"Isambert","year":"2018","journal-title":"Oncoimmunology."},{"issue":"18","key":"10.1016\/j.autrev.2021.102763_bb1275","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1158\/0008-5472.CAN-18-0413","article-title":"IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.autrev.2021.102763_bb1280","article-title":"A pilot, non-randomized evaluation of the safety of anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients","volume":"34","author":"Whiteley","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:11:57Z","timestamp":1778821917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":253,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1568997221000227"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102763","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102763"}}